Harbin Gloria Pharmaceuticals Co., Ltd (002437.SZ)
CNY 2.36
(-1.26%)
CNY 2.36
(-1.26%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 120.33 Million CNY | 141.56% |
| 2022 | -289.51 Million CNY | -742.77% |
| 2021 | 45.04 Million CNY | -88.74% |
| 2020 | 400.04 Million CNY | 115.07% |
| 2019 | -2.65 Billion CNY | -2208.87% |
| 2018 | 125.89 Million CNY | -59.35% |
| 2017 | 309.67 Million CNY | -56.79% |
| 2016 | 716.64 Million CNY | 7.8% |
| 2015 | 664.8 Million CNY | 49.81% |
| 2014 | 443.77 Million CNY | 95.72% |
| 2013 | 226.73 Million CNY | 37.61% |
| 2012 | 164.76 Million CNY | 41.01% |
| 2011 | 116.84 Million CNY | -24.47% |
| 2010 | 154.71 Million CNY | 18.8% |
| 2009 | 130.23 Million CNY | 22.92% |
| 2008 | 105.95 Million CNY | 41.73% |
| 2007 | 74.75 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 52.28 Million CNY | 150.62% |
| 2024 Q3 | 58.51 Million CNY | -19.5% |
| 2024 Q2 | 72.68 Million CNY | 39.03% |
| 2023 Q1 | 20.05 Million CNY | 106.14% |
| 2023 Q3 | 195.37 Million CNY | 2285.4% |
| 2023 Q4 | -103.28 Million CNY | -152.87% |
| 2023 FY | 120.33 Million CNY | 141.56% |
| 2023 Q2 | 8.19 Million CNY | -59.17% |
| 2022 Q2 | 25.87 Million CNY | 2491.73% |
| 2022 Q1 | 998.26 Thousand CNY | 101.52% |
| 2022 Q4 | -326.82 Million CNY | -6033.14% |
| 2022 Q3 | 5.5 Million CNY | -78.71% |
| 2022 FY | -289.51 Million CNY | -742.77% |
| 2021 Q2 | 92.68 Million CNY | 323.11% |
| 2021 FY | 45.04 Million CNY | -88.74% |
| 2021 Q3 | -4.07 Million CNY | -104.4% |
| 2021 Q1 | 21.9 Million CNY | 108.5% |
| 2021 Q4 | -65.47 Million CNY | -1506.94% |
| 2020 Q1 | 658.6 Million CNY | 122.16% |
| 2020 FY | 400.04 Million CNY | 115.07% |
| 2020 Q3 | -11.31 Million CNY | -208.73% |
| 2020 Q4 | -257.64 Million CNY | -2176.35% |
| 2020 Q2 | 10.4 Million CNY | -98.42% |
| 2019 FY | -2.65 Billion CNY | -2208.87% |
| 2019 Q1 | 85.48 Million CNY | 145.43% |
| 2019 Q2 | 146.79 Million CNY | 71.71% |
| 2019 Q3 | 78.03 Million CNY | -46.84% |
| 2019 Q4 | -2.97 Billion CNY | -3908.74% |
| 2018 Q2 | 127.77 Million CNY | 30.17% |
| 2018 Q3 | 88.13 Million CNY | -31.02% |
| 2018 Q1 | 98.15 Million CNY | 334.4% |
| 2018 Q4 | -188.18 Million CNY | -313.51% |
| 2018 FY | 125.89 Million CNY | -59.35% |
| 2017 Q1 | 121.09 Million CNY | -17.4% |
| 2017 FY | 309.67 Million CNY | -56.79% |
| 2017 Q3 | 67.91 Million CNY | -30.75% |
| 2017 Q4 | 22.59 Million CNY | -66.73% |
| 2017 Q2 | 98.06 Million CNY | -19.01% |
| 2016 Q4 | 146.6 Million CNY | -32.14% |
| 2016 Q2 | 189.08 Million CNY | 14.65% |
| 2016 Q1 | 164.91 Million CNY | -0.49% |
| 2016 FY | 716.64 Million CNY | 7.8% |
| 2016 Q3 | 216.04 Million CNY | 14.26% |
| 2015 FY | 664.8 Million CNY | 49.81% |
| 2015 Q3 | 175.38 Million CNY | -11.62% |
| 2015 Q2 | 198.43 Million CNY | 58.41% |
| 2015 Q1 | 125.26 Million CNY | -13.96% |
| 2015 Q4 | 165.73 Million CNY | -5.5% |
| 2014 Q1 | 67.4 Million CNY | -26.43% |
| 2014 FY | 443.77 Million CNY | 95.72% |
| 2014 Q3 | 95.51 Million CNY | -29.38% |
| 2014 Q2 | 135.26 Million CNY | 100.68% |
| 2014 Q4 | 145.58 Million CNY | 52.42% |
| 2013 Q2 | 72.86 Million CNY | 265.25% |
| 2013 Q3 | 42.3 Million CNY | -41.94% |
| 2013 Q4 | 91.61 Million CNY | 116.58% |
| 2013 FY | 226.73 Million CNY | 37.61% |
| 2013 Q1 | 19.94 Million CNY | -69.55% |
| 2012 Q2 | 60.62 Million CNY | 251.93% |
| 2012 Q4 | 65.52 Million CNY | 206.29% |
| 2012 FY | 164.76 Million CNY | 41.01% |
| 2012 Q1 | 17.22 Million CNY | -58.33% |
| 2012 Q3 | 21.39 Million CNY | -64.71% |
| 2011 Q1 | 15.79 Million CNY | -72.34% |
| 2011 Q2 | 48.08 Million CNY | 204.47% |
| 2011 Q3 | 11.62 Million CNY | -75.83% |
| 2011 Q4 | 41.34 Million CNY | 255.76% |
| 2011 FY | 116.84 Million CNY | -24.47% |
| 2010 Q4 | 57.1 Million CNY | 65.12% |
| 2010 Q2 | 47.48 Million CNY | 205.51% |
| 2010 Q3 | 34.58 Million CNY | -27.16% |
| 2010 FY | 154.71 Million CNY | 18.8% |
| 2010 Q1 | 15.54 Million CNY | -71.78% |
| 2009 Q4 | 55.07 Million CNY | 111.0% |
| 2009 FY | 130.23 Million CNY | 22.92% |
| 2009 Q2 | 37.34 Million CNY | 219.13% |
| 2009 Q1 | 11.7 Million CNY | 0.0% |
| 2009 Q3 | 26.1 Million CNY | -30.11% |
| 2008 FY | 105.95 Million CNY | 41.73% |
| 2007 FY | 74.75 Million CNY | 0.0% |